Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Company analysis

Company analysis


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Trends: Hot Topic Catalyst

    $750.00

    The FDA Amendments Act (FDAAA) provided the FDA with new powers in relation to drug safety, including the authority to impose postmarketing requirements (PMRs) and Risk Evaluation and Mitigation Strategies (REMS) on drug manufacturers.

    November 19, 2020
    Find out more
  • JP Morgan Healthcare Conference Review

    $3,000.00

    The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.

    January 18, 2018
    Find out more
  • Acorda Company Analysis

    $3,000.00

    PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.

    February 9, 2018
    Find out more
  • Q2 2016 Earnings Previews

    $3,000.00

    Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

    September 28, 2016
    Find out more
  • Company Analysis: Teva

    $3,000.00

    PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more
  • Company Analysis: Bayer

    $3,000.00

    PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more
  • Company Analysis: Eli Lilly

    $3,000.00

    PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • Company Analysis: Seagen

    $3,000.00

    PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

    January 25, 2021
    Find out more
  • Company Analysis: Vertex

    $3,000.00

    PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

    January 25, 2021
    Find out more
  • Company Analysis: Biogen

    $3,000.00

    PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • Immuno-Oncology Deal Trends, 2012–16

    Immuno-Oncology Deal Trends, 2012–16

    $2,995.00

    Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.

    April 19, 2017
    Find out more
  • Company Analysis: UCB

    $3,000.00

    PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

    January 25, 2021
    Find out more
  • Company Analysis: Merck KGaA

    $3,000.00

    PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

    January 25, 2020
    Find out more
  • big_pharma_diversification_strategies_cover

    Big Pharma Diversification Strategies

    $2,995.00

    Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.

    March 4, 2018
    Find out more
  • Company Analysis: Roche

    $3,000.00

    PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
Page 4 of 5
Page 4 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top